Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

Title: Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

Volume: 10 Issue: 5

Author(s): J. Fraser Wright, Jennifer Wellman and Katherine A. High

Affiliation:

Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography

Abstract: Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.

Cite this article as:

Fraser Wright J., Wellman Jennifer and High A. Katherine, Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65, Current Gene Therapy 2010; 10 (5) . https://dx.doi.org/10.2174/156652310793180715